Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines

Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remi...

Full description

Autores:
Chávez-Castillo, Mervin
Núñez, Victoria
Nava, Manuel
Ortega, Ángel
Rojas, Milagros
Bermúdez, Valmore
Rojas-Quintero, Joselyn
Tipo de recurso:
Fecha de publicación:
2019
Institución:
Universidad Simón Bolívar
Repositorio:
Repositorio Digital USB
Idioma:
eng
OAI Identifier:
oai:bonga.unisimon.edu.co:20.500.12442/2457
Acceso en línea:
http://hdl.handle.net/20.500.12442/2457
Palabra clave:
Depression
Neuroendocrine Disorder
Rights
License
Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
id USIMONBOL2_7a3841c94b525f282394095c02e045f7
oai_identifier_str oai:bonga.unisimon.edu.co:20.500.12442/2457
network_acronym_str USIMONBOL2
network_name_str Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
title Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
spellingShingle Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
Depression
Neuroendocrine Disorder
title_short Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
title_full Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
title_fullStr Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
title_full_unstemmed Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
title_sort Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines
dc.creator.fl_str_mv Chávez-Castillo, Mervin
Núñez, Victoria
Nava, Manuel
Ortega, Ángel
Rojas, Milagros
Bermúdez, Valmore
Rojas-Quintero, Joselyn
dc.contributor.author.none.fl_str_mv Chávez-Castillo, Mervin
Núñez, Victoria
Nava, Manuel
Ortega, Ángel
Rojas, Milagros
Bermúdez, Valmore
Rojas-Quintero, Joselyn
dc.subject.eng.fl_str_mv Depression
Neuroendocrine Disorder
topic Depression
Neuroendocrine Disorder
description Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.
publishDate 2019
dc.date.accessioned.none.fl_str_mv 2019-01-18T21:53:11Z
dc.date.available.none.fl_str_mv 2019-01-18T21:53:11Z
dc.date.issued.none.fl_str_mv 2019
dc.type.eng.fl_str_mv article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv 16876334
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12442/2457
identifier_str_mv 16876334
url http://hdl.handle.net/20.500.12442/2457
dc.language.iso.eng.fl_str_mv eng
language eng
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.license.spa.fl_str_mv Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
rights_invalid_str_mv Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
http://purl.org/coar/access_right/c_abf2
dc.publisher.eng.fl_str_mv Hindawi
dc.source.eng.fl_str_mv Advances in Pharmacological Sciences
institution Universidad Simón Bolívar
dc.source.uri.eng.fl_str_mv https://doi.org/10.1155/2019/7943481
bitstream.url.fl_str_mv https://bonga.unisimon.edu.co/bitstreams/aba00e0a-d89d-4aa4-9af1-453c964aefb0/download
https://bonga.unisimon.edu.co/bitstreams/63ca6155-739c-46b3-887c-ab4772b84f17/download
https://bonga.unisimon.edu.co/bitstreams/5d0c570c-2789-47a9-a1eb-3de79ea78608/download
https://bonga.unisimon.edu.co/bitstreams/73729078-e942-46b1-a9b9-60e9342a883a/download
https://bonga.unisimon.edu.co/bitstreams/413a93b1-5241-472e-9968-16e0cb9f7cf7/download
https://bonga.unisimon.edu.co/bitstreams/1d839f59-bfff-405b-be0d-6d17154bcaa6/download
bitstream.checksum.fl_str_mv 797384b91715c3cc147d28cc80acd6b9
3fdc7b41651299350522650338f5754d
5c9d936d06258a7f82f08641415424cd
c6f94bfd91de3663e11cbddcbc9a246a
f1ae3dac8667f91ca724a8b3194fe18c
73f8411f1b5a3fa51bba8e507650b721
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv repositorio.digital@unisimon.edu.co
_version_ 1812100518228525056
spelling Licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacionalhttp://purl.org/coar/access_right/c_abf2Chávez-Castillo, Mervin3fa71e88-ea60-4874-a359-6e3b8a583df5-1Núñez, Victoria9b360a77-a9bb-4c51-b304-a8f59af2f0a4-1Nava, Manuelf9865b69-841a-4eea-b7da-6a174b033d10-1Ortega, Ángelb6a809bb-4d26-4e53-9419-e4eb9fb40a9b-1Rojas, Milagrosd07a9d4d-cce2-438c-b4a0-fc5ed4af1a67-1Bermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663a-1Rojas-Quintero, Joselyn1fcd6ac1-186e-465c-a5fd-3c25563275ab-12019-01-18T21:53:11Z2019-01-18T21:53:11Z201916876334http://hdl.handle.net/20.500.12442/2457Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.engHindawiAdvances in Pharmacological Scienceshttps://doi.org/10.1155/2019/7943481DepressionNeuroendocrine DisorderDepression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoaminesarticlehttp://purl.org/coar/resource_type/c_6501H. A. Whiteford, A. J. Ferrari, L. Degenhardt, V. Feigin, and T. Vos, “2e global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010,” PLoS One, vol. 10, no. 2, Article ID e0116820, 2015.D. L. Hare, S. R. Toukhsati, P. Johansson, and T. Jaarsma, “Depression and cardiovascular disease: a clinical review,” European Heart Journal, vol. 35, no. 21, pp. 1365–1372, 2013.P. E. Greenberg, A.-A. Fournier, T. Sisitsky, C. T. Pike, and R. C. Kessler, “2e economic burden of adults with major depressive disorder in the United States (2005 and 2010),” Ae Journal of Clinical Psychiatry, vol. 76, no. 2, pp. 155–162, 2015.E. Dale, B. Bang-Andersen, and C. Sánchez, “Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs,” Biochemical Pharmacology, vol. 95, no. 2, pp. 81–97, 2015.S. J. Mathew, H. K. Manji, and D. S. Charney, “Novel drugs and therapeutic targets for severe mood disorders,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2080–2092, 2008.Y. Agid, G. Buzsáki, D. M. Diamond et al., “How can drug discovery for psychiatric disorders be improved?,” Nature Reviews Drug Discovery, vol. 6, no. 3, pp. 189–201, 2007.B. L. Roth, D. J. Sheffler, and W. K. Kroeze, “Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia,” Nature Reviews Drug Discovery, vol. 3, no. 4, pp. 353–359, 2004.T. M. Hillhouse and J. H. Porter, “A brief history of the development of antidepressant drugs: from monoamines to glutamate,” Experimental and Clinical Psychopharmacology, vol. 23, no. 1, pp. 1–21, 2015.M. Hinz, A. Stein, and T. Uncini, “2e discrediting of the monoamine hypothesis,” International Journal of General Medicine, vol. 5, pp. 135–142, 2012.U. E. Lang and S. Borgwardt, “Molecular mechanisms of depression: perspectives on new treatment strategies,” Cellular Physiology and Biochemistry, vol. 31, no. 6, pp. 761–777, 2013.F. Caraci, G. M. Leggio, S. Salomone, and F. Drago, “New drugs in psychiatry: focus on new pharmacological targets,” F1000Research, vol. 6, p. 397, 2017.A. Jansson, “Mood disorders and the brain: depression, melancholia, and the historiography of psychiatry,” Medical History, vol. 55, no. 3, pp. 393–399, 2012.J. Dean and M. Keshavan, “2e neurobiology of depression: an integrated view,” Asian Journal of Psychiatry, vol. 27, pp. 101–111, 2017.F. Orrego and S. Villanueva, “2e chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization,” Neuroscience, vol. 56, no. 3, pp. 539–555, 1993.J. H. Krystal, D. C. D’Souza, I. L. Petrakis et al., “NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders,” Harvard Review of Psychiatry, vol. 7, no. 3, pp. 125–143, 1999.J. H. Krystal, G. Sanacora, and R. S. Duman, “Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond,” Biological Psychiatry, vol. 73, no. 12, pp. 1133–1141, 2013.S. D. Geddes, S. Assadzada, A. Sokolovski, R. Bergeron, S. Haj-Dahmane, and J.-C. B´e¨ıque, “Time-dependent modulation of glutamate synapses onto 5-HT neurons by antidepressant treatment,” Neuropharmacology, vol. 95, pp. 130–143, 2015.D. C. Javitt, D. Schoepp, P. W. Kalivas et al., “Translating glutamate: from pathophysiology to treatment,” Science Translational Medicine, vol. 3, no. 102, p. 102mr2, 2011.X. Fan, W. Y. Jin, and Y. T. Wang, “2e NMDA receptor complex: a multifunctional machine at the glutamatergic synapse,” Frontiers in Cellular Neuroscience, vol. 8, p. 160, 2014.G. Perea, M. Sur, and A. Araque, “Neuron-glia networks: integral gear of brain function,” Frontiers in Cellular Neuroscience, vol. 8, p. 378, 2014.N. Li, B. Lee, R.-J. Liu et al., “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists,” Science, vol. 329, no. 5994, pp. 959– 964, 2010.I. A. Paul and P. Skolnick, “Glutamate and depression,” Annals of the New York Academy of Sciences, vol. 1003, no. 1, pp. 250–272, 2003.R. Trullas and P. Skolnick, “Functional antagonists at the NMDA receptor complex exhibit antidepressant actions,” European Journal of Pharmacology, vol. 185, no. 1, pp. 1–10, 1990.M. Kurdi, K. 2eerth, and R. Deva, “Ketamine: current applications in anesthesia, pain, and critical care,” Anesthesia: Essays and Researches, vol. 8, no. 3, p. 283, 2014.C. A. Zarate, J. B. Singh, P. J. Carlson et al., “A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression,” Archives of General Psychiatry, vol. 63, no. 8, p. 856, 2006.N. Diazgranados, L. Ibrahim, N. E. Brutsche et al., “A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression,” Archives of General Psychiatry, vol. 67, no. 8, pp. 793–802, 2010.G. W. Valentine, G. F. Mason, R. Gomez et al., “2e antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS,” Psychiatry Research: Neuroimaging, vol. 191, no. 2, pp. 122–127, 2011.R. M. Berman, A. Cappiello, A. Anand et al., “Antidepressant effects of ketamine in depressed patients,” Biological Psychiatry, vol. 47, no. 4, pp. 351–354, 2000.S. A. Irwin and A. Iglewicz, “Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care,” Journal of Palliative Medicine, vol. 13, no. 7, pp. 903–908, 2010.C. G. Zanicotti, D. Perez, and P. Glue, “Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer,” Journal of Palliative Medicine, vol. 15, no. 4, pp. 400–403, 2012.K. A. B. Lapidus, C. F. Levitch, A. M. Perez et al., “A randomized controlled trial of intranasal ketamine in major depressive disorder,” Biological psychiatry, vol. 76, no. 12, pp. 970–976, 2014.N. D. Iadarola, M. J. Niciu, E. M. Richards et al., “Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review,” Aerapeutic advances in chronic disease, vol. 6, no. 3, pp. 97–114, 2015.H. Homayoun and B. Moghaddam, “NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons,” Journal of Neuroscience, vol. 27, no. 43, pp. 11496–11500, 2007.A. E. Autry, M. Adachi, E. Nosyreva et al., “NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses,” Nature, vol. 475, no. 7354, pp. 91–95, 2011.M. M. Harraz, R. Tyagi, P. Cortés, and S. H. Snyder, “Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation,” Molecular Psychiatry, vol. 21, no. 3, pp. 313–319, 2016.N. Li, R.-J. Liu, J. M. Dwyer et al., “Glutamate N-methyl-Daspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure,” Biological Psychiatry, vol. 69, no. 8, pp. 754–761, 2011.J. M. Witkin, D. E. Knutson, G. J. Rodriguez, and S. Shi, “Rapid-acting antidepressants,” Current Pharmaceutical Design, vol. 24, no. 22, pp. 2556–2563, 2018.C. Yang, Y. Shirayama, J.-c. Zhang et al., “R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects,” Translational Psychiatry, vol. 5, no. 9, p. e632, 2015.K. Hashimoto and C. Yang, “Is (S)-norketamine an alternative antidepressant for esketamine?,” European Archives of Psychiatry and Clinical Neuroscience, vol. 268, 2018.C. Yang, S. Kobayashi, K. Nakao et al., “AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine,” Biological Psychiatry, vol. 84, no. 8, pp. 591–600, 2018.J. Moskal, J. Burgdorf, P. Stanton et al., “2e development of rapastinel (formerly GLYX-13), a rapid acting and long lasting antidepressant,” Current Neuropharmacology, vol. 15, no. 1, pp. 47–56, 2016.C. I. Rodriguez, J. Zwerling, E. Kalanthroff et al., “Effect of a novel NMDA receptor modulator, rapastinel (formerly GLYX-13), in OCD: proof of concept,” American Journal of Psychiatry, vol. 173, no. 12, pp. 1239–1241, 2016.M. E. d. S. Frizzo, L. P. Dall’Onder, K. B. Dalcin, and D. O. Souza, “Riluzole enhances glutamate uptake in rat astrocyte cultures,” Cellular and Molecular Neurobiology, vol. 24, no. 1, pp. 123–128, 2004.M. Banasr, G. M. I. Chowdhury, R. Terwilliger et al., “Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole,” Molecular Psychiatry, vol. 15, no. 5, pp. 501–511, 2008.P. T¨urck and M. E. Frizzo, “Riluzole stimulates BDNF release from human platelets,” BioMed Research International, vol. 2015, Article ID 189307, 6 pages, 2015.E. H. Wong, J. A. Kemp, T. Priestley, A. R. Knight, G. N. Woodruff, and L. L. Iversen, “2e anticonvulsant MK- 801 is a potent N-methyl-D-aspartate antagonist,” Proceedings of the National Academy of Sciences, vol. 83, no. 18, pp. 7104–7108, 1986.S. Maeng, C. A. Zarate, J. Du et al., “Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors,” Biological Psychiatry, vol. 63, no. 4, pp. 349–352, 2008.S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc, “mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants,” Neuropharmacology, vol. 66, pp. 40–52, 2013.A. Mahapatra and R. Gupta, “Role of psilocybin in the treatment of depression,” Aerapeutic Advances in Psychopharmacology, vol. 7, no. 1, pp. 54–56, 2016.R. L. Carhart-Harris, L. Roseman, M. Bolstridge et al., “Psilocybin for treatment-resistant depression: fMRImeasured brain mechanisms,” Scientific Reports, vol. 7, no. 1, p. 13187, 2017.R. L. Carhart-Harris, M. Bolstridge, C. M. J. Day et al., “Psilocybin with psychological support for treatmentresistant depression: six-month follow-up,” Psychopharmacology, vol. 235, no. 2, pp. 399–408, 2017.M.-N. Quan, N. Zhang, Y.-Y. Wang, T. Zhang, and Z. Yang, “Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model,” Neuroscience, vol. 182, pp. 88–97, 2011.E. J. Lenze, E. R. Skidmore, A. E. Begley, J. W. Newcomer, M. A. Butters, and E. M. Whyte, “Memantine for late-life depression and apathy after a disabling medical event: a 12- week, double-blind placebo-controlled pilot study,” International Journal of Geriatric Psychiatry, vol. 27, no. 9, pp. 974–980, 2011.C. A. Zarate, J. B. Singh, J. A. Quiroz et al., “A double-blind, placebo-controlled study of memantine in the treatment of major depression,” American Journal of Psychiatry, vol. 163, no. 1, pp. 153–155, 2006.S. J. Mathew, J. W. Murrough, M. aan het Rot, K. A. Collins, D. L. Reich, and D. S. Charney, “Riluzole for relapse prevention following intravenous ketamine in treatmentresistant depression: a pilot randomized, placebo-controlled continuation trial,” International Journal of Neuropsychopharmacology, vol. 13, no. 1, pp. 71–82, 2010.L. Ibrahim, N. DiazGranados, J. Franco-Chaves et al., “Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study,” Neuropsychopharmacology, vol. 37, no. 6, pp. 1526–1533, 2012.M. J. Niciu, B. Kelmendi, and G. Sanacora, “Overview of glutamatergic neurotransmission in the nervous system,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 656–664, 2012.C. A. Zarate, J. L. Payne, J. Quiroz et al., “An open-label trial of riluzole in patients with treatment-resistant major depression,” American Journal of Psychiatry, vol. 161, no. 1, pp. 171–174, 2004.E. Salardini, A. Zeinoddini, P. Mohammadinejad et al., “Riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial,” Journal of Psychiatric Research, vol. 75, pp. 24–30, 2016.J. Du, K. Suzuki, Y. Wei et al., “2e anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders,” Neuropsychopharmacology, vol. 32, no. 4, pp. 793–802, 2006.A. Pałucha-Poniewiera and A. Pilc, “Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test,” Progress in Neuro- Psychopharmacology and Biological Psychiatry, vol. 39, no. 1, pp. 102–106, 2012.E. R. Hascup, K. N. Hascup, M. Stephens et al., “Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex,” Journal of Neurochemistry, vol. 115, no. 6, pp. 1608–1620, 2010.J. M. Dwyer, A. E. Lepack, and R. S. Duman, “mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure,” Journal of Molecular Psychiatry, vol. 1, no. 1, p. 15, 2013.J. M. Dwyer, A. E. Lepack, and R. S. Duman, “mTOR activation is required for the antidepressant effects of mGluR2/ 3 blockade,” Ae International Journal of Neuropsychopharmacology, vol. 15, no. 4, pp. 429–434, 2011.A. Pałucha-Poniewiera, B. Szewczyk, and A. Pilc, “Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats,” Neuropharmacology, vol. 82, pp. 59–68, 2014.M. L. Furey, A. Khanna, E. M. Hoffman, and W. C. Drevets, “Scopolamine produces larger antidepressant and antianxiety effects in women than in men,” Neuropsychopharmacology, vol. 35, no. 12, pp. 2479–2488, 2010.B. Voleti, A. Navarria, R.-J. Liu et al., “Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses,” Biological Psychiatry, vol. 74, no. 10, pp. 742–749, 2013.M. Amar, E. Lucas-Meunier, G. Baux, and P. Fossier, “Blockade of different muscarinic receptor subtypes changes the equilibrium between excitation and inhibition in rat visual cortex,” Neuroscience, vol. 169, no. 4, pp. 1610–1620, 2010.M. L. Furey and W. C. Drevets, “Antidepressant efficacy of the antimuscarinic drug scopolamine,” Archives of General Psychiatry, vol. 63, no. 10, p. 1121, 2006.A. Alt, E. S. Nisenbaum, D. Bleakman, and J. M. Witkin, “A role for AMPA receptors in mood disorders,” Biochemical Pharmacology, vol. 71, no. 9, pp. 1273–1288, 2006.W. C. Drevets and M. L. Furey, “Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial,” Biological Psychiatry, vol. 67, no. 5, pp. 432–438, 2010.J. C. Gillin, L. Sutton, C. Ruiz et al., “2e effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group,” Biological Psychiatry, vol. 30, no. 2, pp. 157–169, 1991.K. M. Kantak, “Magnesium deficiency alters aggressive behavior and catecholamine function,” Behavioral Neuroscience, vol. 102, no. 2, pp. 304–311, 1988.H. Murck, “Magnesium and affective disorders,” Nutritional Neuroscience, vol. 5, no. 6, pp. 375–389, 2013.N. Singewald, C. Sinner, A. Hetzenauer, S. B. Sartori, and H. Murck, “Magnesium-deficient diet alters depression- and anxiety-related behavior in mice-influence of desipramine and Hypericum perforatum extract,” Neuropharmacology, vol. 47, no. 8, pp. 1189–1197, 2004.G. A. Eby and K. L. Eby, “Rapid recovery from major depression using magnesium treatment,” Medical Hypotheses, vol. 67, no. 2, pp. 362–370, 2006.G. K. Kirov, N. J. Birch, P. Steadman, and R. G. Ramsey, “Plasma magnesium levels in a population of psychiatric patients: correlations with symptoms,” Neuropsychobiology, vol. 30, no. 2-3, pp. 73–78, 2008.A. Zieba, R. Kata, D. Dudek, M. Schlegel-zawadzka, and G. Nowak, “Serum trace elements in animal models and human depression: Part III. Magnesium. Relationship with copper,” Human Psychopharmacology: Clinical and Experimental, vol. 15, no. 8, pp. 631–635, 2001.M. Watanabe, K. Maemura, K. Kanbara, T. Tamayama, and H. Hayasaki, “GABA and GABA receptors in the central nervous system and other organs,” International Review of Cytology, vol. 213, pp. 1–47, 2002.E. Sigel and M. E. Steinmann, “Structure, function, and modulation of GABAAReceptors,” Journal of Biological Chemistry, vol. 287, no. 48, pp. 40224–40231, 2012.B. Bettler, K. Kaupmann, J. Mosbacher, and M. Gassmann, “Molecular structure and physiological functions of GABABReceptors,” Physiological Reviews, vol. 84, no. 3, pp. 835–867, 2004.G. Sanacora, G. F. Mason, and J. H. Krystal, “Impairment of GABAergic transmission in depression: new insights from neuroimaging studies,” Critical Reviews in Neurobiology, vol. 14, no. 1, pp. 23–45, 2000.J. Fischell, A. M. Van Dyke, M. D. Kvarta, T. A. LeGates, and S. M. 2ompson, “Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors,” Neuropsychopharmacology, vol. 40, no. 11, pp. 2499–2509, 2015.K. G. Lloyd, F. 2uret, and A. Pilc, “Upregulation of gammaaminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock,” J Pharmacol Exp Aer, vol. 235, no. 1, pp. 191–199, 1985.J. A. Cross and R. W. Horton, “Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABAB binding sites: a comparison with 5-HT2 binding site changes,” British Journal of Pharmacology, vol. 93, no. 2, pp. 331–336, 2012.T. R. Berigan, “Psychiatric uses of newer anticonvulsants,” Ae Primary Care Companion to Ae Journal of Clinical Psychiatry, vol. 3, no. 2, pp. 82–84, 2001.A. Foster and J. Kemp, “Glutamate- and GABA-based CNS therapeutics,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 7–17, 2006.P. Zanos, M. E. Nelson, J. N. Highland et al., “A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice,” eNeuro, vol. 4, no. 1, article ENEURO.0285-16.2017, 2017.T. Duka and D. N. Stephens, “Potentiation of the Propunishment, but not the convulsant action of the β-carboline DMCM by naltrexone,” Pharmacology Biochemistry and Behavior, vol. 25, no. 3, pp. 595–598, 1986.E. Castrén, “Neurotrophins and psychiatric disorders,” Neurotrophic Factors, vol. 220, pp. 461–479, 2014.O. Berton and E. J. Nestler, “New approaches to antidepressant drug discovery: beyond monoamines,” Nature Reviews Neuroscience, vol. 7, no. 2, pp. 137–151, 2006.G. Ochs, R. D. Penn, M. York et al., “A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, no. 3, pp. 201–206, 2009.H. Toenen and M. Sendtner, “Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches,” Nature Neuroscience, vol. 5, pp. 1046–1050, 2002.P. D. O’Leary and R. A. Hughes, “Design of potent peptide mimetics of brain-derived neurotrophic factor,” Journal of Biological Chemistry, vol. 278, no. 28, pp. 25738–25744, 2003.S.-W. Jang, X. Liu, M. Yepes et al., “A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone,” Proceedings of the National Academy of Sciences, vol. 107, no. 6, pp. 2687–2692, 2010.C. Liu, C. B. Chan, and K. Ye, “7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNFimplicated human disorders,” Translational Neurodegeneration, vol. 5, no. 1, p. 2, 2016.X. Liu, C.-B. Chan, Q. Qi et al., “Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression,” Journal of Medicinal Chemistry, vol. 55, no. 19, pp. 8524– 8537, 2012.X. Liu, Q. Qi, G. Xiao, J. Li, H. R. Luo, and K. Ye, “Omethylated metabolite of 7,8-dihydroxyflavone activates TrkB receptor and displays antidepressant activity,” Pharmacology, vol. 91, no. 3-4, pp. 185–200, 2013.J. C. Zhang, J. Wu, Y Fujita et al., “Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation,” Int J Neuropsychopharmacol, vol. 18, no. 4, 2014.M. Cazorla, J. Pr´emont, A. Mann, N. Girard, C. Kellendonk, and D. Rognan, “Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice,” Journal of Clinical Investigation, vol. 121, no. 5, pp. 1846–1857, 2011.G. Tamagno and J. Epelbaum, “Editorial: neurological and psychiatric disorders in endocrine diseases,” Frontiers in Endocrinology, vol. 6, p. 75, 2015.A. Badhan, H. Sareen, and J. Trivedi, “Endocrine dysfunctions and psychiatric disorders: understanding an interface,” Indian Journal of Behavioural Sciences, vol. 18, no. 2, pp. 50–64, 2008.M. Altemus, “Hormone-specific psychiatric disorders: do they exist?,” Archives of Women’s Mental Health, vol. 13, no. 1, pp. 25-26, 2010.D. Stenzel and W. B. Huttner, “Role of maternal thyroid hormones in the developing neocortex and during human evolution,” Frontiers in Neuroanatomy, vol. 7, p. 19, 2013.K. N. Fountoulakis, S. Kantartzis, M. Siamouli et al., “Peripheral thyroid dysfunction in depression,” Ae World Journal of Biological Psychiatry, vol. 7, no. 3, pp. 131–137, 2009.D. Ordas and L. Labbate, “Routine screening of thyroid function in patients hospitalized for major depression or dysthymia?,” Annals of Clinical Psychiatry, vol. 7, no. 4, pp. 161–165, 1995.J. D. Davis, R. A. Stern, and L. A. Flashman, “Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly,” Current Psychiatry Reports, vol. 5, no. 5, pp. 384–390, 2003.S. Gulseren, L. Gulseren, Z. Hekimsoy, P. Cetinay, C. Ozen, and B. Tokatlioglu, “Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction,” Archives of Medical Research, vol. 37, no. 1, pp. 133–139, 2006.V. B. Chueire, J. H. Romaldini, and L. S. Ward, “Subclinical hypothyroidism increases the risk for depression in the elderly,” Archives of Gerontology and Geriatrics, vol. 44, no. 1, pp. 21–28, 2007.C. Fekete and R. M. Lechan, “Central regulation of hypothalamic-pituitary-thyroid Axis under physiological and pathophysiological conditions,” Endocrine Reviews, vol. 35, no. 2, pp. 159–194, 2014.M. P. Hage and S. T. Azar, “2e link between thyroid function and depression,” Journal of Ayroid Research, vol. 2012, Article ID 590648, 8 pages, 2012.Y. Mizoguchi, T. A. Kato, Y. Seki et al., “Brain-derived neurotrophic factor (BDNF) induces sustained intracellular Ca2+Elevation through the up-regulation of surface transient receptor potential 3 (TRPC3) channels in rodent microglia,” Journal of Biological Chemistry, vol. 289, no. 26, pp. 18549–18555, 2014.T. A. Kato, Y. Yamauchi, H Horikawa et al., “Neurotransmitters, psychotropic drugs and microglia: clinical implications for psychiatry,” Current Medicinal Chemistry, vol. 20, no. 3, pp. 331–344, 2013.S. Honda, Y. Sasaki, K. Ohsawa et al., “Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/ocoupled P2Y receptors,” Ae Journal of Neuroscience, vol. 21, no. 6, pp. 1975–1982, 2001.H. Kalyanaraman, R. Schwappacher, J. Joshua et al., “Nongenomic thyroid hormone signaling occurs through a plasma membrane-localized receptor,” Science Signaling, vol. 7, no. 326, p. ra48, 2014.Y. Mori, D. Tomonaga, A. Kalashnikova et al., “Effects of 3,3′,5-triiodothyronine on microglial functions,” Glia, vol. 63, no. 5, pp. 906–920, 2015.R. T. Joffe, “Is the thyroid still important in major depression?,” Journal of Psychiatry and Neuroscience, vol. 31, no. 6, pp. 367-368, 2006.O. Agid and B. Lerer, “Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation,” Ae International Journal of Neuropsychopharmacology, vol. 6, no. 1, pp. 41–49, 2003.L. L. Altshuler, M. A. Frye, and M. J. Gitlin, “Acceleration and augmentation strategies for treating bipolar depression,” Biological Psychiatry, vol. 53, no. 8, pp. 691–700, 2003.S. Pridmore and Y. Turnier-Shea, “Medication options in the treatment of treatment-resistant depression,” Australian and New Zealand Journal of Psychiatry, vol. 38, no. 4, pp. 219– 225, 2004.B. Demartini, R. Ranieri, A. Masu, V. Selle, S. Scarone, and O. Gambini, “Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism,” Ae Journal of Nervous and Mental Disease, vol. 202, no. 8, pp. 603–607, 2014.S. J. Claes, “CRH, stress, and major depression: a psychobiological interplay,” Vitamins & Hormones, vol. 69, pp. 117–150, 2004.F. Holsboer, “Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy,” Journal of Affective Disorders, vol. 62, no. 1-2, pp. 77–91, 2001.F. Holsboer and N. Barden, “Antidepressants and hypothalamic-pituitary-adrenocortical regulation,” Endocrine Reviews, vol. 17, no. 2, pp. 187–205, 1996.K. Van Pett, V. Viau, J. C. Bittencourt et al., “Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse,” Ae Journal of Comparative Neurology, vol. 428, no. 2, pp. 191–212, 2000.Z. Liu, F. Zhu, G. Wang et al., “Association of corticotropinreleasing hormone receptor1 gene SNP and haplotype with major depression,” Neuroscience Letters, vol. 404, no. 3, pp. 358–362, 2006.M. L. Wong, J. Licinio, K. I. Pasternak, and P. W. Gold, “Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry,” Endocrinology, vol. 135, no. 5, pp. 2275– 2278, 1994.A. W. Zobel, T. Nickel, H. E. K¨unzel et al., “Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated,” Journal of Psychiatric Research, vol. 34, no. 3, pp. 171–181, 2000.F. Holsboer and M. Ising, “Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists,” European Journal of Pharmacology, vol. 583, no. 2-3, pp. 350–357, 2008.B. Binneman, D. Feltner, S. Kolluri, Y. Shi, R. Qiu, and T. Stiger, “A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1Antagonist) in the treatment of major depression,” American Journal of Psychiatry, vol. 165, no. 5, pp. 617–620, 2008.M. Ising, U. S. Zimmermann, H. E. K¨unzel et al., “Highaffinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response,” Neuropsychopharmacology, vol. 32, no. 9, pp. 1941–1949, 2007.R. Sanghvi, E. Mogalian, S. G. Machatha et al., “Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor,” Journal of Pharmaceutical Sciences, vol. 98, no. 1, pp. 205–214, 2009.M. B. Solomon and J. P. Herman, “Sex differences in psychopathology: of gonads, adrenals and mental illness,” Physiology & Behavior, vol. 97, no. 2, pp. 250–258, 2009.G. B. Parker and H. L. Brotchie, “From diathesis to dimorphism,” Ae Journal of Nervous and Mental Disease, vol. 192, no. 3, pp. 210–216, 2004.S. L. Douma, C. Husband, M. E. OʼDonnell, B. N. Barwin, and A. K. Woodend, “Estrogen-related mood disorders,” Advances in Nursing Science, vol. 28, no. 4, pp. 364–375, 2005.R. C. Kessler, O. Demler, R. G. Frank et al., “Prevalence and treatment of mental disorders, 1990 to 2003,” New England Journal of Medicine, vol. 352, no. 24, pp. 2515–2523, 2005.M. H. J. Bekker and J. van Mens-Verhulst, “Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment,” Gender Medicine, vol. 4, pp. S178–S193, 2007.M. ¨ Osterlund, G.J.M. Kuiper, J.- ˚ A. Gustafsson, and Y. L. Hurd, “Differential distribution and regulation of estrogen receptor-α and -β mRNA within the female rat brain,” Molecular Brain Research, vol. 54, no. 1, pp. 175–180, 1998.S. Grigoriadis and S. H. Kennedy, “Role of estrogen in the treatment of depression,” American Journal of Aerapeutics, vol. 9, no. 6, pp. 503–509, 2002.P. J. Schmidt, L. Nieman, M. A. Danaceau et al., “Estrogen replacement in perimenopause-related depression: a preliminary report,” American Journal of Obstetrics and Gynecology, vol. 183, no. 2, pp. 414–420, 2000.E. L. Klaiber, D. M. Broverman, W. Vogel, and Y. Kobayashi, “Estrogen therapy for severe persistent depressions in women,” Archives of general psychiatry, vol. 36, no. 5, pp. 550–554, 1979.C. E. Gleason, N. M. Dowling, W. Wharton et al., “Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study,” PLoS Medicine, vol. 12, no. 6, article e1001833, 2015.J. M. Whedon, A. KizhakkeVeettil, N. A. Rugo, and K. A. Kieffer, “Bioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis,” Journal of Women’s Health, vol. 26, no. 1, pp. 18–28, 2017.S. J. Jung, A. Shin, and D. Kang, “Hormone-related factors and post-menopausal onset depression: results from KNHANES (2010-2012),” Journal of Affective Disorders, vol. 175, pp. 176–183, 2015.S. Brummelte and L. A. M. Galea, “Postpartum depression: etiology, treatment and consequences for maternal care,” Hormones and Behavior, vol. 77, pp. 153–166, 2016.L. Andréen, S. Nyberg, S. Turkmen, G. van Wingen, G. Fernández, and T. B¨ackström, “Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators,” Psychoneuroendocrinology, vol. 34, no. 8, pp. 1121–1132, 2009.A. Ahokas, J. Kaukoranta, K. Wahlbeck, and M. Aito, “Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17betaestradiol: a preliminary study,” Journal of Clinical Psychiatry, vol. 62, no. 5, pp. 332–336, 2001.K. L. Wisner, D. K. Y. Sit, E. L. Moses-Kolko et al., “Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial,” Journal of Clinical Psychopharmacology, vol. 35, no. 4, pp. 389–395, 2015.S. Kanes, H. Colquhoun, H. Gunduz-Bruce et al., “Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial,” Ae Lancet, vol. 390, no. 10093, pp. 480–489, 2017.E. E. Baulieu and P. Robel, “Neurosteroids: a new brain function?,” Ae Journal of Steroid Biochemistry and Molecular Biology, vol. 37, no. 3, pp. 395–403, 1990.R. C. Melcangi, L. M. Garcia-Segura, and A. G. Mensah- Nyagan, “Neuroactive steroids: state of the art and new perspectives,” Cellular and Molecular Life Sciences, vol. 65, no. 5, pp. 777–797, 2008.R. Rupprecht, “Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties,” Psychoneuroendocrinology, vol. 28, no. 2, pp. 139–168, 2003.B. O. Dubrovsky, “Steroids, neuroactive steroids and neurosteroids in psychopathology,” Progress in Neuro- Psychopharmacology and Biological Psychiatry, vol. 29, no. 2, pp. 169–192, 2005.D. Eser, C. Sch¨ule, T. C. Baghai, E. Romeo, D. P. Uzunov, and R. Rupprecht, “Neuroactive steroids and affective disorders,” Pharmacology Biochemistry and Behavior, vol. 84, no. 4, pp. 656–666, 2006.J. McHenry, N. Carrier, E. Hull, and M. Kabbaj, “Sex differences in anxiety and depression: role of testosterone,” Frontiers in Neuroendocrinology, vol. 35, no. 1, pp. 42–57, 2014.A. H. Ford, B. B. Yeap, L. Flicker et al., “Prospective longitudinal study of testosterone and incident depression in older men: the health in men study,” Psychoneuroendocrinology, vol. 64, pp. 57–65, 2016.C. J. DiBlasio, J. Hammett, J. B. Malcolm et al., “Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer,” Ae Canadian Journal of Urology, vol. 15, no. 5, pp. 4249–4256, 2008.H. G. Pope, R. Amiaz, B. P. Brennan et al., “Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment,” Journal of Clinical Psychopharmacology, vol. 30, no. 2, pp. 126–134, 2010.K. K. Miller, R. H. Perlis, G. I. Papakostas et al., “Low-dose transdermal testosterone augmentation therapy improves depression severity in women,” CNS Spectrums, vol. 14, no. 12, pp. 688–694, 2009.J. Durdiakova, D. Ostatnikova, and P. Celec, “Testosterone and its metabolites–modulators of brain functions,” Acta Neurobiologiae Experimentalis, vol. 71, no. 4, pp. 434–454, 2011.U. D. Rohr, “2e impact of testosterone imbalance on depression and women’s health,” Maturitas, vol. 41, no. 1, pp. 25–46, 2002.A. Locci and G. Pinna, “Neurosteroid biosynthesis downregulation and changes in GABA A receptor subunit composition: a biomarker axis in stress-induced cognitive and emotional impairment: neurosteroids and GABA: biomarkers for emotions,” British Journal of Pharmacology, vol. 174, no. 19, pp. 3226–3241, 2017.T. Bäckström, M. Bixo, M. Johansson et al., “Allopregnanolone and mood disorders,” Progress in Neurobiology, vol. 113, pp. 88–94, 2014.C. C. Smith, T. T. Gibbs, and D. H. Farb, “Pregnenolone sulfate as a modulator of synaptic plasticity,” Psychopharmacology, vol. 231, no. 17, pp. 3537–3556, 2014.M. Schumacher, C. Mattern, A. Ghoumari et al., “Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors,” Progress in Neurobiology, vol. 113, pp. 6–39, 2014.C. E. Schiller, P. J. Schmidt, and D. R. Rubinow, “Allopregnanolone as a mediator of affective switching in reproductive mood disorders,” Psychopharmacology, vol. 231, no. 17, pp. 3557–3567, 2014.C. Schüle, C. Nothdurfter, and R. Rupprecht, “2e role of allopregnanolone in depression and anxiety,” Progress in Neurobiology, vol. 113, pp. 79–87, 2014.National Library of Medicine, A Study to Evaluate SAGE-217 in Subjects with Moderate to Severe Major Depressive Disorder, ClinicalTrials.gov NCT03000530, National Library of Medicine, Bethesda, MD, USA, 2018, http://clinicaltrials. gov/show/NCT03000530.H. Kische, S. Gross, H. Wallaschofski et al., “Associations of androgens with depressive symptoms and cognitive status in the general population,” in PLoS One, B. He, Ed., vol. 12, no. 5, Article ID e0177272, 2017.B. Weber, S. Lewicka, M. Deuschle, M. Colla, and I. Heuser, “Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression,” Psychoneuroendocrinology, vol. 25, no. 8, pp. 765–771, 2000.T. R. Insel, “2e challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior,” Neuron, vol. 65, no. 6, pp. 768–779, 2010.I. D. Neumann and R. Landgraf, “Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors,” Trends in Neurosciences, vol. 35, no. 11, pp. 649–659, 2012.J. A. Barraza and P. J. Zak, “Empathy toward strangers triggers oxytocin release and subsequent generosity,” Annals of the New York Academy of Sciences, vol. 1167, no. 1, pp. 182–189, 2009.V. Morhenn, J. Park, E. Piper, and P. Zak, “Monetary sacrifice among strangers is mediated by endogenous oxytocin release after physical contact,” Evolution and Human Behavior, vol. 29, no. 6, pp. 375–383, 2008.B. Leuner, J. M. Caponiti, and E. Gould, “Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids,” Hippocampus, vol. 22, no. 4, pp. 861–868, 2012.K. W. Yuen, J. P. Garner, D. S. Carson et al., “Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol,” Journal of Psychiatric Research, vol. 51, pp. 30–36, 2014.R. J. McQuaid, O. A. McInnis, A. Abizaid, and H. Anisman, “Making room for oxytocin in understanding depression,” Neuroscience & Biobehavioral Reviews, vol. 45, pp. 305–322, 2014.G. Meynen, U. A. Unmehopa, M. A. Hofman, D. F. Swaab, and W. J. G. Hoogendijk, “Hypothalamic oxytocin mRNA expression and melancholic depression,” Molecular Psychiatry, vol. 12, no. 2, pp. 118-119, 2007.M. R. Melis, T. Melis, C. Cocco et al., “Oxytocin injected into the ventral tegmental area induces penile erection and increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the hypothalamus of male rats: ventral tegmental area, oxytocin and penile erection,” European Journal of Neuroscience, vol. 26, no. 4, pp. 1026– 1035, 2007.J. M. Cantor, Y. M. Binik, and J. G. Pfaus, “Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin,” Psychopharmacology, vol. 144, no. 4, pp. 355–362, 1999.M. Lancel, S. Krömer, and I. D. Neumann, “Intracerebral oxytocin modulates sleep-wake behaviour in male rats,” Regulatory Peptides, vol. 114, no. 2–3, pp. 145–152, 2003.P. Mak, C. Broussard, K. Vacy, and J. H. Broadbear, “Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat,” Journal of Psychopharmacology, vol. 26, no. 4, pp. 532–542, 2012.M. Birnbaumer, “Vasopressin receptors,” Trends in Endocrinology & Metabolism, vol. 11, no. 10, pp. 406–410, 2000.J. Roper, A.-M. O’Carroll, W. Young, and S. Lolait, “2e vasopressin Avpr1b receptor: molecular and pharmacological studies,” Stress, vol. 14, no. 1, pp. 98–115, 2011.S. Jard, C. Barberis, S. Audigier, and E. Tribollet, “Neurohypophyseal hormone receptor systems in brain and periphery,” Progress in Brain Research, vol. 72, pp. 173–187, 1987.M. 2ibonnier, P. Coles, A. 2ibonnier, and M. Shoham, “2e basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists,” Annual Review of Pharmacology and Toxicology, vol. 41, no. 1, pp. 175–202, 2001.N. G. Simon, C. Guillon, K. Fabio et al., “Vasopressin antagonists as anxiolytics and antidepressants: recent developments,” Recent Patents on CNS Drug Discovery, vol. 3, no. 2, pp. 77–93, 2008.G. Griebel and F. Holsboer, “Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?,” Nature Reviews Drug Discovery, vol. 11, no. 6, pp. 462–478, 2012.R. Landgraf, M. S. Keßler, M. Bunck et al., “Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I,” Neuroscience & Biobehavioral Reviews, vol. 31, no. 1, pp. 89–102, 2007.D. Katz, C. Locke, N. Greco, W. Liu, and K. Tracy, “Hypothalamic- pituitary- adrenal axis and depression symptom effects on an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial,” Brain and Behavior, vol. 7, no. 3, article e00628, 2017.M. S. Kramer, N. Cutler, J. Feighner et al., “Distinct mechanism for antidepressant activity by blockade of central substance P receptors,” Science, vol. 281, no. 5383, pp. 1640–1645, 1998.M. Keller, S. Montgomery, W. Ball et al., “Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder,” Biological Psychiatry, vol. 59, no. 3, pp. 216–223, 2006.E. Ratti, P. Bettica, R. Alexander et al., “Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies,” Journal of Psychopharmacology, vol. 27, no. 5, pp. 424–434, 2013.D. F. Ionescu and G. I. Papakostas, “Experimental medication treatment approaches for depression,” Translational Psychiatry, vol. 7, no. 3, p. e1068, 2017.E. Ratti, K. Bellew, P. Bettica et al., “Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder,” Journal of Clinical Psychopharmacology, vol. 31, no. 6, pp. 727–733, 2011.F. Reichmann and P. Holzer, “Neuropeptide Y: a stressful review,” Neuropeptides, vol. 55, pp. 99–109, 2016.N. M. Enman, E. L. Sabban, P. McGonigle, and E. J. Van Bockstaele, “Targeting the neuropeptide Y system in stress-related psychiatric disorders,” Neurobiology of Stress, vol. 1, pp. 33–43, 2015.J. P. Redrobe, Y. Dumont, and R. Quirion, “Neuropeptide Y (NPY) and depression: from animal studies to the human condition,” Life Sciences, vol. 71, no. 25, pp. 2921–2937, 2002.H. Hashimoto, “Plasma neuropeptide Y in patients with major depressive disorder,” Neuroscience Letters, vol. 216, no. 1, pp. 57–60, 1996.M. Heilig, “Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism,” J. Psychiatr. Res.vol. 38, no. 2, pp. 113–121, 2004.S. Ozsoy, O. Olguner Eker, and U. Abdulrezzak, “2e effects of antidepressants on neuropeptide Y in patients with depression and anxiety,” Pharmacopsychiatry, vol. 49, no. 1, pp. 26–31, 2016.J. Redrobe, “2e neuropeptide Y (NPY) Y1 receptor subtype mediates NPY- induced antidepressant-like activity in the mouse forced swimming test,” Neuropsychopharmacology, vol. 26, no. 5, pp. 615–624, 2002.J. P. Redrobe, “Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test,” Peptides, vol. 26, no. 8, pp. 1394–1400, 2005.K. A. Stogner and P. V. Holmes, “Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats,” European Journal of Pharmacology, vol. 387, no. 2, pp. R9– R10, 2000.H. Ishida, “Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor,” Hippocampus, vol. 17, no. 4, pp. 271–280, 2007.E. Painsipp, H. Herzog, and P. Holzer, “Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice,” Neuropharmacology, vol. 55, no. 1, pp. 117–126, 2008.R. O. Tasan, “Increased novelty-induced motor activity and reduced depression-like behavior in neuropeptide Y (NPY)- Y4 receptor knockout mice,” Neuroscience, vol. 158, no. 4, pp. 1717–1730, 2009.X. Zhao, R. R. Seese, K. Yun, T. Peng, and Z. Wang, “2e role of galanin system in modulating depression, anxiety, and addiction-like behaviors after chronic restraint stress,” Neuroscience, vol. 246, pp. 82–93, 2013.E. Kuteeva, T. H¨okfelt, T. Wardi, and S. O. Ogren, “Galanin, Galanin Receptor Subtypes and Depression-Like Behaviour,” in Experientia Supplementum, vol. 102, pp. 163–181, 2010.C. Millón, A. Flores-Burgess, M. Narváez et al., “2e neuropeptides Galanin and Galanin(1–15) in depression-like behaviours,” Neuropeptides, vol. 64, pp. 39–45, 2017.G. Juhasz, G. Hullam, N. Eszlari et al., “Brain galanin system genes interact with life stresses in depression-related phenotypes,” Proceedings of the National Academy of Sciences, vol. 111, no. 16, pp. E1666–E1673, 2014.Y.-J. Wang, Y.-T. Yang, H. Li, P.-Z. Liu, C.-Y. Wang, and Z.-Q. D. Xu, “Plasma galanin is a biomarker for severity of major depressive disorder,” Ae International Journal of Psychiatry in Medicine, vol. 48, no. 2, pp. 109–119, 2014.A. Flores-Burgess, C. Mill´on, B. Gago et al., “Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression,” Neuropharmacology, vol. 118, pp. 233– 241, 2017.I. Saar, J. Lahe, K. Langel et al., “Novel systemically active galanin receptor 2 ligands in depression-like behavior,” Journal of Neurochemistry, vol. 127, no. 1, pp. 114–123, 2013.I. Saar, J. Runesson, J. J¨arv, K. Kurrikoff, and ¨U Langel, “Novel galanin receptor subtype specific ligand in depression like behavior,” Neurochemical Research, vol. 38, no. 2, pp. 398–404, 2013.A. M. Barr, J. W. Kinney, M. N. Hill et al., “A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests,” Neuroscience Letters, vol. 405, no. 1-2, pp. 111–115, 2006.C. J. Swanson, T. P. Blackburn, X. Zhang et al., “From the Cover: anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299,” Proceedings of the National Academy of Sciences, vol. 102, no. 48, pp. 17489–17494, 2005.S. N. Haber and B. Knutson, “2e reward circuit: linking primate anatomy and human imaging,” Neuropsychopharmacology, vol. 35, no. 1, pp. 4–26, 2010.A. Alcaro, R. Huber, and J. Panksepp, “Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective,” Brain Research Reviews, vol. 56, no. 2, pp. 283–321, 2007.S. J. Russo and E. J. Nestler, “2e brain reward circuitry in mood disorders,” Nature Reviews Neuroscience, vol. 14, no. 9, pp. 609–625, 2013.M. Heshmati and S. J. Russo, “Anhedonia and the brain reward circuitry in depression,” Current Behavioral Neuroscience Reports, vol. 2, no. 3, pp. 146–153, 2015.E. J. Nestler, “Role of the brain’s reward circuitry in depression: transcriptional mechanisms,” International Review of Neurobiology, vol. 124, pp. 151–170, 2015.B. W. Dunlop and C. B. Nemeroff, “2e role of dopamine in the pathophysiology of depression,” Archives of General Psychiatry, vol. 64, no. 3, p. 327, 2007.K. C. Berridge, C.-Y. Ho, J. M. Richard, and A. G. DiFeliceantonio, “2e tempted brain eats: pleasure and desire circuits in obesity and eating disorders,” Brain Research, vol. 1350, pp. 43–64, 2010.L. Perogamvros and S. Schwartz, “2e roles of the reward system in sleep and dreaming,” Neuroscience & Biobehavioral Reviews, vol. 36, no. 8, pp. 1934–1951, 2012.P. Robledo, F. Berrendero, A. Ozaita, and R. Maldonado, “Advances in the field of cannabinoid-opioid cross-talk: advances in cannabinoid-opioid cross-talk,” Addiction Biology, vol. 13, no. 2, pp. 213–224, 2008.A. Perchuk, S. M. Bierbower, A. Canseco-Alba et al., “Developmental and behavioral effects in neonatal and adult mice following prenatal activation of endocannabinoid receptors by capsaicin,” Acta Pharmacologica Sinica, 2018.A. T. Knoll and W. A. Carlezon, “Dynorphin, stress, and depression,” Brain Research, vol. 1314, pp. 56–73, 2010.P.-E. Lutz and B. L. Kieffer, “Opioid receptors: distinct roles in mood disorders,” Trends in Neurosciences, vol. 36, no. 3, pp. 195–206, 2013.P. L. Tenore, “Psychotherapeutic benefits of opioid agonist therapy,” Journal of Addictive Diseases, vol. 27, no. 3, pp. 49–65, 2008.J. Le Merrer, J. A. J. Becker, K. Befort, and B. L. Kieffer, “Reward processing by the opioid system in the brain,” Physiological Reviews, vol. 89, no. 4, pp. 1379–1412, 2009.E. Berrocoso, P. Sánchez-Blázquez, J. Garzón, and J. A. Mico, “Opiates as antidepressants,” Current Pharmaceutical Design, vol. 15, no. 14, pp. 1612–1622, 2009.S. Scarone, O. Gambini, G. Calabrese et al., “Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data,” Psychiatry Research, vol. 32, no. 2, pp. 159–166, 1990.S. E. Kennedy, R. A. Koeppe, E. A. Young, and J.-K. Zubieta, “Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women,” Archives of General Psychiatry, vol. 63, no. 11, p. 1199, 2006.J.-K. Zubieta, T. A. Ketter, J. A. Bueller et al., “Regulation of human affective responses by anterior cingulate and limbic μ-opioid neurotransmission,” Archives of General Psychiatry, vol. 60, no. 11, p. 1145, 2003.G. Zalsman, A. Molcho, Y. Huang, A. Dwork, S. Li, and J. J. Mann, “Postmortem mu-opioid receptor binding in suicide victims and controls,” Journal of Neural Transmission, vol. 112, no. 7, pp. 949–954, 2005.S. C. Ribeiro, S. E. Kennedy, Y. R. Smith, C. S. Stohler, and J.-K. Zubieta, “Interface of physical and emotional stress regulation through the endogenous opioid system and μ-opioid receptors,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 29, no. 8, pp. 1264–1280, 2005.J. F. Scherrer, J. Salas, L. A. Copeland et al., “Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients,” Ae Journal of Pain, vol. 17, no. 4, pp. 473–482, 2016.A. Grattan, M. D. Sullivan, K. W. Saunders, C. I. Campbell, and M. R. Von Korff, “Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse,” Ae Annals of Family Medicine, vol. 10, no. 4, pp. 304–311, 2012.J. O. Merrill, M. Von Korff, C. J. Banta-Green et al., “Prescribed opioid difficulties, depression and opioid dose among chronic opioid therapy patients,” General Hospital Psychiatry, vol. 34, no. 6, pp. 581–587, 2012.J. F. Scherrer, D. M. Svrakic, K. E. Freedland et al., “Prescription opioid analgesics increase the risk of depression,” Journal of General Internal Medicine, vol. 29, no. 3, pp. 491–499, 2014.E. Berrocoso, K. Ikeda, I. Sora, G. R. Uhl, P. Sánchez- Blázquez, and J. A. Mico, “Active behaviours produced by antidepressants and opioids in the mouse tail suspension test,” Ae International Journal of Neuropsychopharmacology, vol. 16, no. 1, pp. 151–162, 2013.R. Vergura, G. Balboni, B. Spagnolo et al., “Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2- COOH)- Bid (UFP-512), a novel selective delta opioid receptor agonist,” Peptides, vol. 29, no. 1, pp. 93–103, 2008.C. Contet, B. L. Kieffer, and K. Befort, “Mu opioid receptor: a gateway to drug addiction,” Current Opinion in Neurobiology, vol. 14, no. 3, pp. 370–378, 2004.M. Fava, A. Memisoglu, M. E. 2ase et al., “Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial,” American Journal of Psychiatry, vol. 173, no. 5, pp. 499–508, 2016.Z. Benyhe, G. Toth, M. Wollemann et al., “Effects of synthetic analogues of human opiorphin on rat brain opioid receptors,” Journal of Physiology and Pharmacology, vol. 65, no. 4, pp. 525–530, 2014.H. Javelot, M. Messaoudi, S. Garnier, and C. Rougeot, “Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways,” Journal of Physiology and Pharmacology, vol. 61, no. 3, pp. 355–362, 2010.Q.-Z. Yang, S.-S. Lu, X.-Z. Tian, A.-M. Yang, W.-W. Ge, and Q. Chen, “The antidepressant- like effect of human opiorphin via opioid-dependent pathways in mice,” Neuroscience Letters, vol. 489, no. 2, pp. 131–135, 2011.V. Di Marzo, A. Fontana, H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandamide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994.T. Sugiura, S. Kondo, A. Sukagawa et al., “Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca2+-dependent transacylase and phosphodiesterase activities,” Biochemical and Biophysical Research Communications, vol. 218, no. 1, pp. 113–117, 1996.Z. E. Zajkowska, A. Englund, and P. A. Zunszain, “Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response,” Pharmacogenomics, vol. 15, no. 5, pp. 687–698, 2014.A. Agrawal, E. C. Nelson, A. K. Littlefield et al., “Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression,” Archives of General Psychiatry, vol. 69, no. 7, pp. 732–740, 2012.M. Mitjans, C. Gastó, R. Catalán, L. Fañanás, and B. Arias, “Genetic variability in the endocannabinoid system and 12- week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes,” Journal of Psychopharmacology, vol. 26, no. 10, pp. 1391–1398, 2012.L. Colino, J. Herranz-Herrer, E. Gil-Benito et al., “Cannabinoid receptors, mental pain and suicidal behavior: a systematic review,” Current Psychiatry Reports, vol. 20, no. 3, p. 19, 2018.L. Kranaster, C. Hoyer, S. S. Aksay et al., “Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study,” European Archives of Psychiatry and Clinical Neuroscience, vol. 267, no. 8, pp. 781–786, 2017.S. Jeon and Y.-K. Kim, “Molecular neurobiology and promising new treatment in depression,” International Journal of Molecular Sciences, vol. 17, no. 3, p. 381, 2016.K. Starowicz, L. Cristino, and V. Di Marzo, “TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications,” Current Pharmaceutical Design, vol. 14, no. 1, pp. 42–54, 2008.N. Khairatkar-Joshi and A. Szallasi, “TRPV1 antagonists: the challenges for therapeutic targeting,” Trends in Molecular Medicine, vol. 15, no. 1, pp. 14–22, 2009.E. E. Benarroch, “2e locus ceruleus norepinephrine system: functional organization and potential clinical significance,” Neurology, vol. 73, no. 20, pp. 1699–1704, 2009.I. J. You, Y. H. Jung, M. J. Kim et al., “Alterations in the emotional and memory behavioral phenotypes of transient receptor potential vanilloid type 1-deficient mice are mediated by changes in expression of 5-HT1 A, GABA(A), and NMDA receptors,” Neuropharmacology, vol. 62, no. 2, pp. 1034–1043, 2012.S. S. Manna and S. N. Umathe, “A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine,” European Journal of Pharmacology, vol. 685, no. 1–3, pp. 81–90, 2012.T. Hayase, “Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors,” BMC Pharmacology, vol. 11, no. 1, p. 6, 2011.National Library of Medicine, Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients (Ketamine), ClinicalTrials.gov. NCT02935595, http:// clinicaltrials.gov/show/NCT02935595, National Library of Medicine, Bethesda, MD, USA, 2018.National Library of Medicine, Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer, ClinicalTrials.gov. NCT02836288, http://clinicaltrials.gov/show/NCT02836288, National Library of Medicine, Bethesda, MD, USA, 2018.ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf4203568https://bonga.unisimon.edu.co/bitstreams/aba00e0a-d89d-4aa4-9af1-453c964aefb0/download797384b91715c3cc147d28cc80acd6b9MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-8368https://bonga.unisimon.edu.co/bitstreams/63ca6155-739c-46b3-887c-ab4772b84f17/download3fdc7b41651299350522650338f5754dMD52TEXTDepression as a Neuroendocrine Disorder_Emerging.pdf.txtDepression as a Neuroendocrine Disorder_Emerging.pdf.txtExtracted texttext/plain117128https://bonga.unisimon.edu.co/bitstreams/5d0c570c-2789-47a9-a1eb-3de79ea78608/download5c9d936d06258a7f82f08641415424cdMD53PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain101392https://bonga.unisimon.edu.co/bitstreams/73729078-e942-46b1-a9b9-60e9342a883a/downloadc6f94bfd91de3663e11cbddcbc9a246aMD55THUMBNAILDepression as a Neuroendocrine Disorder_Emerging.pdf.jpgDepression as a Neuroendocrine Disorder_Emerging.pdf.jpgGenerated Thumbnailimage/jpeg1638https://bonga.unisimon.edu.co/bitstreams/413a93b1-5241-472e-9968-16e0cb9f7cf7/downloadf1ae3dac8667f91ca724a8b3194fe18cMD54PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5453https://bonga.unisimon.edu.co/bitstreams/1d839f59-bfff-405b-be0d-6d17154bcaa6/download73f8411f1b5a3fa51bba8e507650b721MD5620.500.12442/2457oai:bonga.unisimon.edu.co:20.500.12442/24572024-07-26 03:12:31.076open.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.coPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj48aW1nIGFsdD0iTGljZW5jaWEgQ3JlYXRpdmUgQ29tbW9ucyIgc3R5bGU9ImJvcmRlci13aWR0aDowIiBzcmM9Imh0dHBzOi8vaS5jcmVhdGl2ZWNvbW1vbnMub3JnL2wvYnktbmMvNC4wLzg4eDMxLnBuZyIgLz48L2E+PGJyLz5Fc3RhIG9icmEgZXN0w6EgYmFqbyB1bmEgPGEgcmVsPSJsaWNlbnNlIiBocmVmPSJodHRwOi8vY3JlYXRpdmVjb21tb25zLm9yZy9saWNlbnNlcy9ieS1uYy80LjAvIj5MaWNlbmNpYSBDcmVhdGl2ZSBDb21tb25zIEF0cmlidWNpw7NuLU5vQ29tZXJjaWFsIDQuMCBJbnRlcm5hY2lvbmFsPC9hPi4=

Publicaciones similares